Pharmaceutical Technology2h
Climb Bio enters licensing deal with Mabworks for CLYM116 development
Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising CLYM116.
Pharmaceutical Technology5h
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.
Pharmaceutical Technology5h
Light Horse emerges with $62m and Novartis partnership worth up to $1bn
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
Pharmaceutical Technology10h
Synaffix secures ADC deals with Boehringer and Mitsubishi Tanabe
Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.